These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19597474)

  • 1. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression.
    Said N; Frierson HF; Chernauskas D; Conaway M; Motamed K; Theodorescu D
    Oncogene; 2009 Oct; 28(39):3487-98. PubMed ID: 19597474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer.
    Wong SY; Crowley D; Bronson RT; Hynes RO
    Clin Exp Metastasis; 2008; 25(2):109-18. PubMed ID: 18058030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
    Jain AK; Raina K; Agarwal R
    Cell Cycle; 2013 May; 12(10):1598-604. PubMed ID: 23624841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone.
    Sharma S; Xing F; Liu Y; Wu K; Said N; Pochampally R; Shiozawa Y; Lin HK; Balaji KC; Watabe K
    J Biol Chem; 2016 Sep; 291(37):19351-63. PubMed ID: 27422817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P21 and P27 promote tumorigenesis and progression via cell cycle acceleration in seminal vesicles of TRAMP mice.
    Li T; Wang F; Dang Y; Dong J; Zhang Y; Zhang C; Liu P; Gao Y; Wang X; Yang S; Lu S
    Int J Biol Sci; 2019; 15(10):2198-2210. PubMed ID: 31592235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer.
    Ramu I; Buchholz SM; Patzak MS; Goetze RG; Singh SK; Richards FM; Jodrell DI; Sipos B; Ströbel P; Ellenrieder V; Hessmann E; Neesse A
    EBioMedicine; 2019 Oct; 48():161-168. PubMed ID: 31597597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations.
    Mateo F; Meca-Cortés O; Celià-Terrassa T; Fernández Y; Abasolo I; Sánchez-Cid L; Bermudo R; Sagasta A; Rodríguez-Carunchio L; Pons M; Cánovas V; Marín-Aguilera M; Mengual L; Alcaraz A; Schwartz S; Mellado B; Aguilera KY; Brekken R; Fernández PL; Paciucci R; Thomson TM
    Mol Cancer; 2014 Oct; 13():237. PubMed ID: 25331979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice.
    Williams TM; Hassan GS; Li J; Cohen AW; Medina F; Frank PG; Pestell RG; Di Vizio D; Loda M; Lisanti MP
    J Biol Chem; 2005 Jul; 280(26):25134-45. PubMed ID: 15802273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Secreted Protein, Acidic and Rich in Cysteine in Prostate Carcinogenesis: Development of a 3D Nanostructured Bone-Like Model.
    Ribeiro N; Costa-Pinheiro P; Henrique R; Gomez-Lazaro M; Pereira MP; Mansur AAP; Mansur HS; Jerónimo C; Sousa SR; Monteiro FJ
    J Biomed Nanotechnol; 2016 Aug; 12(8):1667-78. PubMed ID: 29342345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis.
    Puolakkainen PA; Brekken RA; Muneer S; Sage EH
    Mol Cancer Res; 2004 Apr; 2(4):215-24. PubMed ID: 15140943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
    Peek EM; Song W; Zhang H; Huang J; Chin AI
    Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.
    Enriquez C; Cancila V; Ferri R; Sulsenti R; Fischetti I; Milani M; Ostano P; Gregnanin I; Mello-Grand M; Berrino E; Bregni M; Renne G; Tripodo C; Colombo MP; Jachetti E
    Cancer Res; 2021 Aug; 81(16):4257-4274. PubMed ID: 34185677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal expression of decorin, Semaphorin6D, SPARC, Sprouty1 and Tsukushi in developing prostate and decreased levels of decorin in prostate cancer.
    Henke A; Grace OC; Ashley GR; Stewart GD; Riddick AC; Yeun H; O'Donnell M; Anderson RA; Thomson AA
    PLoS One; 2012; 7(8):e42516. PubMed ID: 22880013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
    Alcaraz LB; Mallavialle A; David T; Derocq D; Delolme F; Dieryckx C; Mollevi C; Boissière-Michot F; Simony-Lafontaine J; Du Manoir S; Huesgen PF; Overall CM; Tartare-Deckert S; Jacot W; Chardès T; Guiu S; Roger P; Reinheckel T; Moali C; Liaudet-Coopman E
    Theranostics; 2021; 11(13):6173-6192. PubMed ID: 33995652
    [No Abstract]   [Full Text] [Related]  

  • 16. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth.
    Prada F; Benedetti LG; Bravo AI; Alvarez MJ; Carbone C; Podhajcer OL
    J Invest Dermatol; 2007 Nov; 127(11):2618-28. PubMed ID: 17625595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoglin regulates cancer-stromal cell interactions in prostate tumors.
    Romero D; O'Neill C; Terzic A; Contois L; Young K; Conley BA; Bergan RC; Brooks PC; Vary CP
    Cancer Res; 2011 May; 71(10):3482-93. PubMed ID: 21444673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
    Liu T; Qiu X; Zhao X; Yang R; Lian H; Qu F; Li X; Guo H
    Oncol Rep; 2018 Feb; 39(2):659-666. PubMed ID: 29207175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
    Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
    Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
    Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
    Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.